A prospective study of the use of botulinum toxin injections in the treatment of Raynaud’s syndrome associated with scleroderma

• Published in: The Journal of hand surgery, European volume European volume, 2014-10, Vol.39 (8), p.876-880
• Main Authors: Uppal, L., Dhaliwal, K., Butler, P. E.
• Format: Article
• Language: English
• Subjects: Adult; Botulinum Toxins, Type A - therapeutic use; Disability Evaluation; Female; Hand Strength; Humans; Injections, Intramuscular; Middle Aged; Neuromuscular Agents - therapeutic use; Prospective Studies; Range of Motion, Articular; Raynaud Disease - drug therapy; Raynaud Disease - etiology; Scleroderma, Systemic - complications; Visual Analog Scale; Young Adult
• ISSN: 1753-1934; 2043-6289
• DOI: 10.1177/1753193413516242

Raynaud’s syndrome contributes to the pain, paraesthesia, ulceration, and gangrene of scleroderma. Botulinum toxin has been shown to improve digital perfusion in patients with Raynaud’s. This is the first study to objectively assess hand function following this treatment in patients with scleroderma. Twenty patients were treated with 100 units of botulinum toxin injected into the hand. An assessment of hand function and symptoms was performed prior to injection and then 8–12 weeks later. The outcomes assessed were change in pain, appearance, cold intolerance, pinch and power grip, ranges of movement, and Disabilities of the Arm, Shoulder and Hand (DASH) score. In total, 80% of patients reported an overall improvement in their symptoms, reduction in pain, and improved DASH score and 65% reported improvement in cold intolerance. Overall, 90% showed an improvement in pinch grip and 65% an improvement in power grip. Objective parameters were statistically significantly improved; however, subjective outcomes only showed a trend. We have found botulinum toxin to be an effective treatment for Raynaud’s syndrome secondary to scleroderma.